Use your antibodies-online credentials, if available.
PCSK9 encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. 再加上，我们可以发PCSK9 抗体 (160) 和 PCSK9 蛋白 (64)和数多这个蛋白质的别的产品。
Showing 10 out of 77 products:
Human PCSK9 ELISA Kit for Sandwich ELISA - ABIN2345049
Jin, Park, Kim, Vaziri: Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study. in American journal of kidney diseases : the official journal of the National Kidney Foundation 2014
Show all 3 Pubmed References
Mouse (Murine) PCSK9 ELISA Kit for Sandwich ELISA - ABIN2685159
Seidah, Benjannet, Wickham, Marcinkiewicz, Jasmin, Stifani, Basak, Prat, Chretien: The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. in Proceedings of the National Academy of Sciences of the United States of America 2003
Show all 3 Pubmed References
Human PCSK9 ELISA Kit for Sandwich ELISA - ABIN820112
Dogan, Akman, Simsek, Ozdem, Comak, Gokceoglu, Kardelen, Koyun: Assessment of left ventricular function by tissue Doppler echocardiography in pediatric chronic kidney disease. in Renal failure 2015
Show all 2 Pubmed References
Rare variants of APOB (显示 APOB ELISA试剂盒) or PCSK9 were identified in nine of the 22 study patients with extremely low LDL-C levels
PCSK9 plays a direct role on Abca1 (显示 ABCA1 ELISA试剂盒)-mediated cholesterol efflux through a downregulation of Abca1 (显示 ABCA1 ELISA试剂盒) gene and Abca1 (显示 ABCA1 ELISA试剂盒) protein expression. This extrahepatic effect may influence relevant steps in the pathogenesis of atherosclerosis, such as foam cell formation.
kidney function per se does not impact significantly PCSK9 metabolism
Sirolimus therapy in heart transplant patients is associated with elevation in PCSK9 levels which is not associated with sirolimus-induced hypercholesterolemia.
PCSK9 inhibits lipoprotein(a) clearance through the LDLR (显示 LDLR ELISA试剂盒).
PCSK9 variants reduced fasting LDL-C as well as fasting triglycerides.
Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR (显示 LDLR ELISA试剂盒) mutations modifies the phenotype of familial hypercholesterolemia
PCSK9 associated with Familial Hypercholesterolemia and Polygenic Hypercholesterolemia in patients with Acute Coronary Syndrome , age =65 years, and LDL-C levels >/=160 mg/dl.
Results clearly that PCSK9 serum concentrations were associated to liver function and mortality, pointed to the disturbance of steroid regulation in patients with end-stage liver disease and an association of such disturbance with mortality. Further studies are required to acquire a more detailed understanding of the role of PCSK9 in liver-related mortality.
Use Crispr-Cas (显示 CSE1L ELISA试剂盒) system to introduce nonsense variants into PCSK9 to lower blood cholesterol levels.
Use Crispr-Cas (显示 CTNND1 ELISA试剂盒) system to introduce nonsense variants into PCSK9 to lower blood cholesterol levels.
Studied the combination model of a single AAV-PCSK9 injection, high-fat diet, and partial carotid ligation which induces robust atherosclerosis in the flow-disturbed carotid artery within 3 weeks in C57 mice, and results suggest this is a quick and convenient model to study atherosclerosis and mechanisms using any knockout or transgenic mice without having to generate double knockouts.
These observations suggest positive feedback interplay between SMC (显示 DYM ELISA试剂盒)-derived PCSK9 and mtDNA damage in the proinflammatory milieu involving mtROS. This interaction results in cellular injury, characterized by apoptosis-a hallmark of atherosclerosis.
AdipoR activation by agonists regulated PCSK9 expression and inhibits atherosclerosis in apoE (显示 APOE ELISA试剂盒)(-/-) mice.
Adeno (显示 ADORA2A ELISA试剂盒)-associated virus mediated infection with a mouse PCSK9 gain-of-function mutation is a rapid, easy, and efficient approach for inducing hypercholesterolemia and promoting abdominal aortic aneurysms in C57BL/6 mice infused with angiotensin II.
conditions that cause ER stress regardless of their ability to dysregulate ER Ca(2 (显示 CA2 ELISA试剂盒)+) inhibit PCSK9 secretion, thereby reducing PCSK9-mediated LDLR (显示 LDLR ELISA试剂盒) degradation and promoting LDLR (显示 LDLR ELISA试剂盒)-dependent hepatic cholesterol uptake.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor (显示 LDLR ELISA试剂盒) Degradation.
PCSK9 increases hepatic lipid and lipoprotein production via apoE (显示 APOE ELISA试剂盒)- and LDLR (显示 LDLR ELISA试剂盒)-dependent mechanisms
Podocyte damage triggers marked inductions in plasma PCSK9, and knockout of Pcsk9 ameliorates dyslipidemia in a mouse model of nephrotic syndrome.
This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. The encoded protein is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum. The protein may function as a proprotein convertase. This protein plays a role in cholesterol homeostasis and may have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a third form of autosomal dominant familial hypercholesterolemia (HCHOLA3).
proprotein convertase subtilisin/kexin type 9
, convertase subtilisin/kexin type 9 preproprotein
, neural apoptosis regulated convertase 1
, subtilisin/kexin-like protease PC9
, convertase subtilisin
, neural apoptosis-regulated convertase 1
, proprotein convertase 9
, proprotein convertase PC9
, proprotein convertase subtilisin/kexin type 9 preproprotein
, Proprotein convertase 9
, Subtilisin/kexin-like protease PC9